Tumor suppressor p53 deficiency increases tumor immunogenicity through promoting IL33-mediated anti-tumor immune responses

• Published in: bioRxiv
• Main Authors: Li, Yang, Gao, David Shihong, Yi, Lixian, Gao, Fei, Sun, Runzi, Lu, Kevin Kai, Xu, Junchi, Shoush, Jason, Kykrou, Zoi, Liang, Minxin, Lu, Binfeng
• Format: Paper
• Language: English
• Published: Cold Spring Harbor Laboratory 13.09.2022
• Edition: 1.1
• Subjects: Immunology

Recent studies have shown that p53 contributes to poor survival during immune checkpoint blockade (ICB) therapy. Lung cancer patients with p53 mutations have significantly improved response rates to PD-1 ICB therapy. While previous studies have shown that tumor-derived IL-33 is required for the anti...